Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development Post author: Post published:June 17, 2024 Post category:uncategorized Ready-to-use kit enables detection of binding antibodies against AAV vectors without the need for serotype-specific assays. You Might Also Like UVA scientists develop AI tools to accelerate new drug discovery April 9, 2026 New analysis demonstrates a link between air pollution and cardiovascular disease-related deaths February 7, 2024 Breakthrough miniaturized brain-machine interface enables brain-to-text communication August 27, 2024
New analysis demonstrates a link between air pollution and cardiovascular disease-related deaths February 7, 2024
Breakthrough miniaturized brain-machine interface enables brain-to-text communication August 27, 2024